Megan Douglas
Family Medicine · Low Moor, VANPI 1144865932
Payments from drug & device makers
Across 89 payments — averaging $18.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$364
- AbbVie$300
- Novo Nordisk$242
- Pfizer$98
- Medtronic$93
- Lilly USA, LLC$92
- plus $488 from 12 others
What the payments were for
- Food & beverage$1,65499%
- Education$231%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 18 | $364 |
| AbbVie | 17 | $300 |
| Novo Nordisk | 9 | $242 |
| Pfizer | 6 | $98 |
| Medtronic | 3 | $93 |
| Lilly USA, LLC | 6 | $92 |
| Boehringer Ingelheim | 5 | $90 |
| Amarin Pharma, Inc. | 4 | $68 |
| Otsuka America Pharmaceutical, Inc. | 3 | $65 |
| GSK | 4 | $60 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $45 |
| Merck | 3 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $44 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
| Biogen | 1 | $13 |
| Almatica Pharma LLC | 1 | $12 |
How this compares
$1,677 in reported general payments places this provider in the 75th percentile of 2,553 family medicine providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 26 | $28,332 |
| FarxigaDapagliflozin Propanediol | 30 | $27,821 |
| OzempicSemaglutide | 16 | $24,645 |
| EliquisApixaban | 16 | $24,156 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $21,780 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $14,883 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 20 | $4,345 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $2,733 |
| Potassium Chloride | 48 | $1,232 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 39 | $1,030 |
| Levothyroxine Sodium | 110 | $946 |
| Glipizide ErGlipizide | 25 | $932 |
| Metoprolol Succinate | 40 | $876 |
| Losartan Potassium | 72 | $807 |
| Rosuvastatin Calcium | 52 | $766 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $364 | $42,70444 claims |
| Boehringer IngelheimJardiance | $90 | $28,33226 claims |
| GSKTrelegy Ellipta, Shingrix | $60 | $26,12542 claims |
| Novo NordiskOzempic | $242 | $24,64516 claims |
| PfizerEliquis | $98 | $24,15616 claims |
| Almatica Pharma LLCSertraline Hcl | $12 | $33426 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,553 family medicine providers in Virginia.
Other family medicine in Low Moor
- Aaron HartmanMidlothian$17.4M
- John ScottGlen Allen$16.7M
- Banu MyneniPortsmouth$12.8M
- Patricia HouserWinchester$3.5M
- Stephan JannachDanville$3M
- Linda SchneiderHampton$2.1M
- Jennifer BrownMidlothian$1.3M
- Brian McCormickHampton$793K
- Jerome DanielNorth Chesterfield$779K
- Samir AbdelshaheedChesapeake$642K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.